Others have combined ADCs with EGFR TKIs, notably amivantamab and lazertinib (MARISOPA), which has been shown to be effective, receiving approval from the FDA as a first-line treatment for locally advanced/metastatic NSCLC with exon 19 deletion or exon 21 L858R substitution mutation in 2024 [38,54]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.